Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 260

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 260
---
 our board of directors regarding the composition and chairmanship of 
 the committees of our board of directors;                                                                      |

| • |     | instituting plans or programs for the continuing education of our board of directors and orientation of new 
 directors;                                                                                                  |

| • |     | developing and making recommendations to our board of directors regarding corporate governance guidelines and 
 matters; and                                                                                                  |

| • |     | overseeing periodic evaluations of the board of directors’ performance, including committees of the board of 
 directors.                                                                                                   |

The nominating and corporate governance committee will operate under a written charter, to be effective immediately prior to the closing of this offering, which satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. Code of Business Conduct and Ethics Prior to the closing of this offering, we intend to adopt a written code of business conduct and ethics, or the Code of Conduct, that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar functions. Following this offering, a copy of the Code of Conduct will be available on the Corporate Governance section of our website, https://lbpharma.us/. We intend to disclose on our website any future amendments of our Code of Conduct or waivers that exempt any of the principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions or our directors from provisions in the Code of Conduct. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus. We have included our website in this prospectus solely as an inactive textual reference. Compensation Committee Interlocks and Insider Participation None of our current or former executive officers serve as a member of the compensation committee. None of our officers serve, or have served during the last completed fiscal year, on the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. Non-Employee Director Compensation Historically, we have not had a formal compensation policy with respect to service on our board of directors. In 2024, only our non-employeedirectors, Mr. Garland and Dr. Ruffolo, Jr., received cash fees and option awards in respect of their board service, as shown in the table below. We did not provide compensation for 2024 to our investor designee directors. We have reimbursed and